Optimizing investigator-led oncology research in Europe

Haematologica

Volumn 97, Issue 6, 2012, Pages 800-804

  Barbui, Tiziano ^a   Björkholm, Magnus ^b   Gratwohl, Alois ^c  

^a Ospedali Riuniti Bergamo   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

BREAST CANCER; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; EUROPE; FUNDING; HEALTH CARE NEED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LICENCE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EUROPE; FINANCIAL MANAGEMENT; HUMANS; MEDICAL ONCOLOGY; RESEARCH PERSONNEL;

EID: 84862137599     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.064873     Document Type: Editorial

References (24)

1. Commission of the European Communities (2009). Regulation (EC) n. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. http://ec.europa.eu/ health/files/eudralex/vol-1/reg_2004_726_cons/reg_2004_ 726_cons_en.pdf (accessed Dec 9, 2011).
2. Council of the European Communities. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal of the European Union 1989;L040:8-11.
3. Ridley DB. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet. 2010;376(9744):922-7.
4. Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess. 2005;1: Doc 09.
5. European Federation of Pharmaceutical Industries and Associations. Patients W.A.I.T. indicator: 2010 report-based on EFPIA's database (first EU marketing authorisation in the period 2007-'09). http://www.efpia.eu/content/default.asp?PageID=559&DocID=10200 (accessed Dec 9, 2011).
6. European Parliament and the Council of the European Union Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Union 2001;L121:34p44.
7. Commission of the European Communities. Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorisation of the manufacturing or importation of such products. Official Journal of the European Union 2005;L91:13-9.
8. van Vyve D. Facing the Challenges of the European Clinical Trials Directive: the European Organisation for Research and Treatment of Cancer perspective. Eur Oncol. 2008;4:1
9. Frewer LJ, Coles D, van der Lans IA, Schroeder D, Champion K, Apperley JF. Impact of the European Clinical Trials Directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplant. 2011;46:(3)443-7.
10. Hemminki A, Kellokumpu-Lehtinen P-L. harmful impact of EU clinical trials directive. BMJ. 2006;332(7540):501-2.
11. Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and activity of cancer research. Mol Oncol. 2008;2(1):20-32.
12. Booth CM, Cescon DW, Wang L, Tannock IF, Kryzankowska MK. Evolution of the randomized control trial in oncology over three decades. J Clin Oncol. 2008;26(33):558-64.
13. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5.
14. Kanavos P, Sullivan R, Lewison G, Schurer W, Eckhouse S, Vlachopioti Z; European Cancer Research Managers Forum. The role of funding and policies on innovation in cancer drug development. London: London School of Economics and Political Science, 2009.
15. WHO. Cancer: fact sheet n. 297. http://www.who.int/mediacentre/ factsheets/fs297/en/ (last accessed Dec 6, 2011).
16. McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol 2009; 20(3):403-12.
17. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) (2005). Guideline on the evaluation of anticancer medicinal products in Man http://www.emea.europa.eu/pdfs/human/ ewp/020595en.pdf (accessed Dec 9, 2011).
18. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8(4):935-8.
19. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, et al. Rationale of the biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004;10(11):3885-96.
20. Montedori A, Bonacini MI, Casazza G, Luchetta ML, Duca P, Cozzolino F, Abraha I. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials 2011; 12:58.
21. Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011;343:d4849. doi: 10.1136/bmj.d4849.
22. Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ. 2011;342:d2291. doi: 10.1136/bmj.d2291.
23. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley J. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol. 2011;29(15):1980-6.
24. Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet 2011;378:1777-8.